After finishing at $1.53 in the prior trading day, Akebia Therapeutics Inc. (NASDAQ: AKBA) closed at $1.46, down -4.58%. On the day, 4097350 shares were traded.
Ratios:
Our goal is to gain a better understanding of AKBA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.03 and its Current Ratio is at 1.18.
On August 28, 2023, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $3.75.
Piper Sandler Upgraded its Neutral to Overweight on May 31, 2023, whereas the target price for the stock was revised from $2 to $4.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 29 ’24 when Butler John P. sold 46,570 shares for $1.58 per share. The transaction valued at 73,581 led to the insider holds 2,044,580 shares of the business.
Dahan Michel sold 8,661 shares of AKBA for $13,684 on Feb 29 ’24. The SVP, Chief Operating Officer now owns 706,932 shares after completing the transaction at $1.58 per share. On Feb 29 ’24, another insider, Burke Steven Keith, who serves as the SVP, Chief Medical Officer of the company, sold 7,169 shares for $1.58 each. As a result, the insider received 11,327 and left with 695,840 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.57.
Stock Price History:
Over the past 52 weeks, AKBA has reached a high of $2.48, while it has fallen to a 52-week low of $0.59.
Shares Statistics:
A total of 194.58M shares are outstanding, with a floating share count of 186.68M. Insiders hold about 10.84% of the company’s shares, while institutions hold 18.43% stake in the company.
Earnings Estimates
Its stock is currently analyzed by Akebia Therapeutics, Inc. different market analysts. The consensus estimate for the next quarter is $46.19, with high estimates of $4.13 and low estimates of $11.76.
Analysts are recommending an EPS of between $Healthcare and $Consumer Cyclical for the fiscal current year, implying an average EPS of $Technology.
